Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Generate Biomedicines, Inc.

Generate Biomedicines, Inc. (GENB) Stock Overview

Explore Generate Biomedicines, Inc.’s financial performance, market position, analyst ratings, and future outlook.

GENB●NASDAQ
HealthcareBiotechnology
$17.38
$0.24(1.40%)
U.S. Market opens in 12h 10m

Generate Biomedicines, Inc. (GENB)

Meyka AI Score

Z

Key Financials

Market Cap2.2B
P/E Ratio-16.42
EPS (TTM)$-2.09
ROE-0.27%
Fundamental Analysis

AI Price Forecasts

1 Month$17.04
3 Months$17.51
1 Year Target$18.45

GENB Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Generate Biomedicines, Inc. (NASDAQ: GENB) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Generate Biomedicines, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of GENB on the NASDAQ shows an RSI of 59.58, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $18.45 for the NASDAQ listing.

Key metrics behind Generate Biomedicines, Inc.'s NASDAQ-traded stock include a P/E ratio of -16.42 and a market capitalization of 2.2B. Combined with our AI analysis, these give both institutional and retail investors a clear view of GENB on the NASDAQ.

Price Performance (NASDAQ: GENB)

1-Day Change
1.40%
5-Day Change
8.02%
1-Month Change
7.82%
3-Month Change
9.38%
6-Month Change
41.65%
Year-to-Date (YTD) Change
37.39%
1-Year Change
37.39%
3-Year Change
37.39%
5-Year Change
37.39%
All-Time (Max) Change
37.39%

Contact Information

https://generatebiomedicines.com
1 888 469 0055
101 South Street, Somerville, MA, 02143

Company Facts

3,120 Employees
IPO DateFeb 27, 2026
CountryUS
Actively Trading

Frequently Asked Questions